Janux Therapeutics, Inc. $JANX Shares Purchased by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. increased its stake in Janux Therapeutics by 6.7% during the first quarter, owning approximately 3.85% of the company, valued at $61.5 million.
• Multiple hedge funds have significantly increased their positions in Janux Therapeutics, with GAMMA Investing LLC growing its stake by 1,574% and US Bancorp DE by 2,402.9%.
• Analysts maintain a consensus rating of "Buy" for Janux Therapeutics, with a current average price target of $86.90.

Vanguard Group Inc. lifted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 6.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,278,660 shares of the company's stock after purchasing an additional 142,328 shares during the period. Vanguard Group Inc. owned about 3.85% of Janux Therapeutics worth $61,524,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of JANX. RA Capital Management L.P. increased its holdings in Janux Therapeutics by 13.1% in the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after buying an additional 1,200,000 shares during the last quarter. Paradigm Biocapital Advisors LP increased its holdings in Janux Therapeutics by 46.5% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after buying an additional 1,115,412 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock valued at $190,617,000 after buying an additional 1,038,996 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Janux Therapeutics by 596.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock valued at $59,429,000 after buying an additional 950,557 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Janux Therapeutics by 1,165.6% in the fourth quarter. Bank of America Corp DE now owns 794,761 shares of the company's stock valued at $42,552,000 after buying an additional 731,962 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on JANX. Raymond James Financial initiated coverage on Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price on the stock. Piper Sandler initiated coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They issued an "overweight" rating and a $42.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $86.90.

Janux Therapeutics Trading Down 1.4%

Shares of NASDAQ:JANX traded down $0.33 on Friday, reaching $22.72. 456,346 shares of the company were exchanged, compared to its average volume of 814,947. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -12.62 and a beta of 2.86. Janux Therapeutics, Inc. has a 1-year low of $21.97 and a 1-year high of $71.71. The company has a 50-day moving average of $24.52 and a 200-day moving average of $27.22.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.